Heat Biologics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HTBX research report →
Companywww.heatbio.com
Heat Biologics, Inc. , an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases.
- CEO
- Jeffrey Wolf
- IPO
- 2013
- Employees
- 49
- HQ
- Morrisville, NC, US
Price Chart
Valuation
- Market Cap
- $61.07M
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -2.19
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 43.13%
- Op Margin
- -612.35%
- Net Margin
- -702.87%
- ROE
- -17391.43%
- ROIC
- -359.64%
Growth & Income
- Revenue
- $2.11M · -28.33%
- Net Income
- $-35,400,807 · -35.90%
- EPS
- $-1.41 · 13.50%
- Op Income
- $-35,419,039
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $10.85
- 52W Low
- $1.60
- 50D MA
- $2.57
- 200D MA
- $4.11
- Beta
- 0.30
- Avg Volume
- 155.10K
Get TickerSpark's AI analysis on HTBX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 30, 21 | Smith Edward B III | other | 32,467 |
| Dec 30, 21 | Smith Edward B III | other | 32,467 |
| Dec 13, 21 | Smith Edward B III | other | 32,467 |
| Dec 13, 21 | Ostrander William L. | other | 68,807 |
| Jan 4, 21 | Smith Edward B III | other | 65,217 |
| Jan 4, 21 | Ostrander William L. | other | 51,487 |
| Nov 12, 20 | Smith Edward B III | sell | 103,304 |
| Aug 13, 20 | Ostrander William L. | other | 15,625 |
| Aug 13, 20 | Ostrander William L. | other | 15,625 |
| Aug 13, 20 | Ostrander William L. | other | 4,440 |
Our HTBX Coverage
We haven't published any research on HTBX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HTBX Report →